Occlutech Holding AG Feed

2024-08-28 07:00:00 Occlutech® Announces Commercial Cases of Occlutech ASD Occluder Device Implantation in the U.S.

2024-01-08 08:00:00 Occlutech® Announces FDA Approval of its Occlutech® ASD Occluder and Occlutech® Pistol Pusher, a Minimally Invasive Cardiac Device and Delivery System to Treat Atrial Septal Defects

2023-09-05 08:00:00 Occlutech Q2 2023 – Continued strong revenue growth

2023-09-05 08:00:00 Occlutech Q2 2023 – Fortsatt stark intäktstillväxt

2023-05-26 08:00:00 Occlutech Q1 2023 – Growth momentum with increased sales and marketing activities

2023-05-26 08:00:00 Occlutech Q1 2023 – Tillväxtmomentum med ökade försäljnings- och marknadsaktiviteter

2023-05-23 14:00:00 Occlutech publishes Annual and Sustainability Report 2022

2023-05-23 14:00:00 Occlutech publicerar års- och hållbarhetsredovisning 2022

2023-05-03 08:00:00 Occlutech Bokslutskommuniké 2022 – Betydande ökning av försäljningstillväxten när transformationsprocesser närmar sig sitt slut

2023-05-03 08:00:00 Occlutech Year-end report 2022 – Significant uptick in sales growth as transformation processes are reaching an end

2023-04-05 08:00:00 Occlutech receives subscription commitment of bonds amounting to EUR 40 million in nominal value under a total frame of EUR 75 million to finance US expansion and growth

2023-04-05 08:00:00 Occlutech erhåller teckningsåtagande av obligationer till ett nominellt värde om 40 miljon euro under en ram om 75 miljoner euro för att finansiera expansion i USA och tillväxt

2023-03-13 08:00:00 Occlutech announces first patient enrollment in important US pivotal study for the Atrial Flow Regulator (FROST-HF)

2023-03-13 08:00:00 Occlutech meddelar första patientrekryteringen i viktig amerikansk studie för Atrial Flow Regulator (FROST-HF)

2023-02-01 08:00:00 Occlutech meddelar förändring i koncernledningen

2023-02-01 08:00:00 Occlutech announces change to the Executive Management Team

2023-01-31 08:00:00 Occlutech continues its progress in US FDA study OCCLUFLEX – enrolls first patient in Europe

2023-01-31 08:00:00 Occlutech fortsätter göra framsteg i den amerikanska FDA-studien OCCLUFLEX - rekryterar första patienten i Europa

2022-11-24 11:00:00 Occlutech Q3 2022 – Revenue growth, increased market activity and operational preparations

2022-11-24 11:00:00 Occlutech Q3 2022 – Intäktstillväxt, ökad marknadsaktivitet och operativa förberedelser

2022-11-01 08:00:00 Occlutech announces new member to the Executive Management Team by appointing Chief Medical Officer

2022-11-01 08:00:00 Occlutech meddelar ny medlem till koncernledningen – utser Chief Medical Officer

2022-09-06 08:00:00 Occlutech announces new members to the Executive Management Team – appoints Chief Commercial Officer and Vice President Global Business Development & Marketing

2022-09-06 08:00:00 Occlutech utökar koncernledningen med nya medlemmar – utser Chief Commercial Officer och Vice President Global Business Development & Marketing

2022-08-24 07:30:00 Occlutech Q2 2022 – Positive revenue growth and important milestones achieved in the strategic US market

2022-08-24 07:30:00 Occlutech Q2 2022 – God intäktsökning och viktiga milstolpar uppnådda på den strategiska USA-marknaden

2022-05-31 07:30:00 Occlutech Q1 2022 – Strong revenue increase and important milestones achieved in the strategic US market

2022-05-31 07:30:00 Occlutech Q1 2022 – Kraftig intäktsökning och viktiga milstolpar uppnådda på den strategiska USA-marknaden

2022-05-31 07:15:00 Occlutech announces changes to the Executive Management Team

2022-05-31 07:15:00 Occlutech genomför förändringar i koncernledningen

2022-05-19 14:30:00 Occlutech signs exclusive US distribution agreement with B. Braun Interventional Systems Inc., an Affiliate of B. Braun Medical Inc.

2022-05-19 14:30:00 Occlutech tecknar exklusivt distributionsavtal med B. Braun Interventional Systems Inc., affiliate till B. Braun Medical Inc.

2022-05-12 10:30:00 Occlutech progress in the US – first patient has been enrolled in important US FDA study

2022-05-12 10:30:00 Occlutech gör framsteg i USA – första patienten har rekryterats till viktig amerikansk FDA-studie

2021-12-21 07:30:00 Occlutech has successfully completed a Private Placement of 450 MSEK to support growth

2021-12-21 07:30:00 Occlutech har framgångsrikt genomfört en riktad nyemission om 450 MSEK i syfte att finansiera tillväxt

2021-11-04 07:15:00 Occlutech continues positive progress in the U.S. – granted conditional FDA approval for Heart Failure study for AFR device

2021-11-04 07:15:00 Occlutech fortsätter göra positiva framsteg i USA – erhåller villkorat godkännande från FDA för hjärtsviktsstudie avseende AFR-enhet

2021-09-28 20:40:00 Occlutech chooses to withdraw contemplated IPO

2021-09-28 20:40:00 Occlutech beslutar att dra tillbaka planerad börsintroduktion

2021-09-16 11:30:00 Occlutech publishes prospectus in connection with its initial public offering of Swedish Depository Receipts on Nasdaq First North Premier Growth Market in Stockholm

2021-09-16 11:30:00 Occlutech publicerar prospekt i samband med noteringen av svenska depåbevis på Nasdaq First North Premier Growth Market i Stockholm

2021-09-08 07:00:00 Occlutech announces its intention to launch an initial public offering of Swedish Depository Receipts on Nasdaq First North Premier Growth Market in Stockholm

2021-09-08 07:00:00 Occlutech offentliggör sin avsikt att genomföra en notering av svenska depåbevis på Nasdaq First North Premier Growth Market i Stockholm

2021-08-23 07:30:00 Occlutech strengthens the organization with three new members of Group Management

2021-08-23 07:30:00 Occlutech förstärker organisationen med tre nya medlemmar i koncernledningen

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode